NIKKEI 225
38,913.48 +296.38 (+0.77%) HANG SENG
18,871.23 -324.37 (-1.69%) CRUDE OIL
77.03 -0.54 (-0.70%) GOLD FUTURES
2,370.70 -22.20 (-0.93%) DOW
39,671.04 -201.95 (-0.51%) Bitcoin GBP
54,578.96 -378.88 (-0.69%)
Daiichi Sankyo Company, Limited (D4S.F)
| Previous close | 32.00 |
| Open | 31.49 |
| Bid | 31.53 x 50000 |
| Ask | 32.48 x 50000 |
| Day's range | 31.49 - 31.49 |
| 52-week range | 22.35 - 34.48 |
| Volume | |
| Avg. volume | 116 |
| Market cap | 61.06B |
| Beta (5Y monthly) | 0.26 |
| PE ratio (TTM) | 51.62 |
| EPS (TTM) | 0.61 |
| Earnings date | 29 Jul 2024 - 02 Aug 2024 |
| Forward dividend & yield | 0.36 (1.13%) |
| Ex-dividend date | 27 Sept 2024 |
| 1y target est | N/A |
Business WireDaiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO
BASKING RIDGE, N.J., May 21, 2024--Daiichi Sankyo Highlights Progress in Creating New Standards of Care for Patients Across Multiple Cancers at ASCO
ZacksAstraZeneca (AZN) to Build $1.5B Cancer Drug Plant in Singapore
This new plant will be AstraZeneca's (AZN) first manufacturing facility for producing novel antibody drug conjugates from start to finish. It is scheduled to open in 2029.
BenzingaHeart Disease Drugmaker Esperion Therapeutics Reports Highest Revenue Yet, Stock Soars
Tuesday, Esperion Therapeutics (NASDAQ:ESPR) reported first-quarter revenues of $137.74 million, up 467% Y/Y, surpassing the consensus of $84.51 million. The company reported an EPS of $0.34, a turnaround from an EPS loss of $(0.79) a year ago, beating the consensus of $0.05. U.S. net product revenue was $24.8 million, up approximately 46% Y/Y. Collaboration revenue was $113.0 million, compared to $7.3 million a year ago, driven by increased tablet sales to international partners and sales growt
